Repare Therapeutics (NASDAQ:RPTX) Given New $25.00 Price Target at Piper Sandler

Repare Therapeutics (NASDAQ:RPTXGet Rating) had its price objective reduced by stock analysts at Piper Sandler from $40.00 to $25.00 in a report released on Tuesday, The Fly reports. Piper Sandler’s price objective points to a potential upside of 104.42% from the stock’s current price.

Several other analysts also recently issued reports on RPTX. The Goldman Sachs Group initiated coverage on Repare Therapeutics in a report on Thursday, March 17th. They issued a “buy” rating and a $43.00 price target for the company. Zacks Investment Research downgraded Repare Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Repare Therapeutics has a consensus rating of “Buy” and a consensus price target of $44.50.

RPTX stock opened at $12.23 on Tuesday. The company has a market cap of $512.14 million, a price-to-earnings ratio of -4.34 and a beta of 0.60. The business has a fifty day simple moving average of $14.06 and a 200-day simple moving average of $19.04. Repare Therapeutics has a 52 week low of $9.59 and a 52 week high of $35.75.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.05. Repare Therapeutics had a negative return on equity of 41.95% and a negative net margin of 1,406.68%. The firm had revenue of $6.88 million during the quarter, compared to the consensus estimate of $3.54 million. As a group, equities analysts forecast that Repare Therapeutics will post -3.58 earnings per share for the current year.

In related news, major shareholder Bvf Partners L. P/Il purchased 997,961 shares of Repare Therapeutics stock in a transaction dated Wednesday, January 19th. The shares were acquired at an average price of $14.10 per share, with a total value of $14,071,250.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 30.30% of the company’s stock.

Several hedge funds have recently modified their holdings of RPTX. Deep Track Capital LP bought a new position in shares of Repare Therapeutics during the fourth quarter worth about $44,289,000. Affinity Asset Advisors LLC bought a new position in shares of Repare Therapeutics during the fourth quarter worth about $5,732,000. Redmile Group LLC lifted its position in shares of Repare Therapeutics by 8.6% during the fourth quarter. Redmile Group LLC now owns 2,789,496 shares of the company’s stock worth $58,830,000 after purchasing an additional 221,800 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Repare Therapeutics by 237.3% during the third quarter. Franklin Resources Inc. now owns 298,609 shares of the company’s stock worth $7,836,000 after purchasing an additional 210,074 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Repare Therapeutics during the fourth quarter worth about $3,940,000. 69.41% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Read More

The Fly logo

Analyst Recommendations for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.